Investigational Drug Information for Huperzine-A
✉ Email this page to a colleague
What is the drug development status for Huperzine-A?
Huperzine-A is an investigational drug.
There have been 13 clinical trials for Huperzine-A.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2009.
The most common disease conditions in clinical trials are Cognitive Dysfunction, Alzheimer Disease, and Hemorrhage. The leading clinical trial sponsors are U.S. Army Medical Research and Materiel Command, Yale University, and Shandong Luye Pharmaceutical Co., Ltd.
Summary for Huperzine-A
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,839 |
| WIPO Patent Applications | 756 |
| Japanese Patent Applications | 258 |
| Clinical Trial Progress | Phase 2 (2009-12-01) |
| Vendors | 76 |
Recent Clinical Trials for Huperzine-A
| Title | Sponsor | Phase |
|---|---|---|
| The Effect of Huperzine A Injection on Postoperative Cognitive Dysfunction in Patients With Aneurysmal Subarachnoid Hemorrhage: a Pilot Study | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 4 |
| The Effect of Huperzine A Injection on Postoperative Cognitive Dysfunction in Patients With Aneurysmal Subarachnoid Hemorrhage: a Pilot Study | Wanbangde Pharmaceutical Group Co., LTD | Phase 4 |
| A Study of Huperzine A Injection in Reducing Postoperative Delirium in Elderly Patients Undergoing Non-cardiac Surgery | Second Affiliated Hospital of Wenzhou Medical University | N/A |
Clinical Trial Summary for Huperzine-A
Top disease conditions for Huperzine-A
Top clinical trial sponsors for Huperzine-A
US Patents for Huperzine-A
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
